Basal proteinuria as a prognostic factor in patients with metastatic colorectal cancer treated with bevacizumab - 27/05/14
, Hakan Bozcuk b, Sema Sezgin Göksu b, Ali Murat Tatlı b, Deniz Arslan b, Seyda Gündüz b, Hasan Senol Coskun b, Mustafa Ozdogan c, Burhan Savas bBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 4 |
| Iconographies | 2 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Background |
The beneficial effects of bevacizumab, a widely used agent in metastatic colorectal cancer (mCRC), on clinical survival have been proven. This study investigated the correlation of the clinical benefits and prognosis with proteinuria and other parameters.
Methods |
The study included mCRC patients receiving bevacizumab. Hypertension, 24-hour urine proteinuria, and other routine parameters were recorded at baseline and at certain intervals during treatment.
Results |
The study included 36 consecutive patients. The median progression-free survival (PFS) duration was 10.9±2.6months, and the median overall survival (OS) was 23±3.1months. The median PFS was 7.2months among patients with basal proteinuria above 114mg/day, whereas the median PFS was 12months among patients with an equal or lower level (P=0.010). Similarly, PFS was shorter in patients with high lactate dehydrogenase (LDH) or carcinoembryonic antigen (CEA) levels (LDH, P=0.022; CEA, P=0.014). Bevacizumab response's performance status was good (P=0.05) and was even better in patients with a single liver metastasis (P=0.034) or hypertension (P=0.034).
Conclusions |
We demonstrated that high basal proteinuria, LDH, or CEA levels may be negative prognostic factors in mCRC patients receiving bevacizumab.
Le texte complet de cet article est disponible en PDF.Keywords : Bevacizumab, Metastatic colorectal cancer, Prognostic and predictive factors, Proteinuria
Plan
Vol 68 - N° 4
P. 409-412 - mai 2014 Retour au numéro
Article précédent
- Enhanced expression of long non-coding RNA ZXF1 promoted the invasion and metastasis in lung adenocarcinoma
- Li Zhang, Xue-Feng Zhou, Gao-Feng Pan, Jin-Ping Zhao
- The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma
- M.R. Pelizzo, C. Dobrinja, E. Casal Ide, M. Zane, O. Lora, A. Toniato, C. Mian, S. Barollo, M. Izuzquiza, J. Guerrini, N. De Manzini, I. Merante Boschin, D. Rubello
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?